A Study to Assess The Relative Bioavailability of New Tablet Formulations of GSK1265744 in Healthy Adult Subjects

NCT02059031 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Infection, Human Immunodeficiency Virus

Interventions

DRUG: GSK1265744 Reference formulation
DRUG: GSK1265744 New formulation 1
DRUG: GSK1265744 New formulation 2

Sponsor

ViiV Healthcare